Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at , first published .
Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Mark Jarrett 1*, MBA, MD;  Warren Licht 1*, MD;  Kevin Bock 1*, MHCDS, MD;  Zenobia Brown 1*, MPH, MD;  Jamie Hirsch 1*, MA, MSB, MD;  Kevin Coppa 2*, BSc;  Rajdeep Brar 1*, MD;  Stephen Bello 2*, PA, MHCDS;  Ira Nash 1*, MD

1 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University , Hempstead, NY, US

2 Northwell Health , New Hyde Park, NY, US

*all authors contributed equally

Corresponding Author:

  • Mark Jarrett, MBA, MD
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • Hofstra University
  • 500 Hofstra University
  • Hempstead, NY
  • US
  • Phone: 1 516-463-7516
  • Email: mjarrett@northwell.edu